Nektar Therapeutics (NASDAQ:NKTR) Expected to Announce Earnings of -$0.80 Per Share

Brokerages expect Nektar Therapeutics (NASDAQ:NKTR) to report earnings of ($0.80) per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings. The highest EPS estimate is ($0.75) and the lowest is ($0.86). Nektar Therapeutics posted earnings of $5.33 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 115%. The firm is scheduled to report its next earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($3.14) per share for the current year, with EPS estimates ranging from ($3.30) to ($3.00). For the next fiscal year, analysts forecast that the company will post earnings of ($2.91) per share, with EPS estimates ranging from ($3.92) to ($2.21). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The company had revenue of $28.22 million during the quarter, compared to analyst estimates of $25.45 million. During the same quarter in the previous year, the firm posted ($0.60) EPS.

NKTR has been the subject of a number of analyst reports. Leerink Swann initiated coverage on Nektar Therapeutics in a research report on Friday, March 15th. They set a “market perform” rating for the company. HC Wainwright reiterated a “hold” rating and set a $47.00 price target on shares of Nektar Therapeutics in a research report on Monday, March 4th. Piper Jaffray Companies set a $100.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 1st. Mizuho reiterated a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 1st. Finally, BidaskClub lowered Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. Nektar Therapeutics has an average rating of “Buy” and a consensus target price of $68.50.

NKTR stock traded down $1.33 during trading on Wednesday, reaching $33.29. 1,158,299 shares of the company’s stock were exchanged, compared to its average volume of 1,681,339. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $69.76. The company has a fifty day simple moving average of $33.40. The stock has a market capitalization of $5.91 billion, a price-to-earnings ratio of 8.81 and a beta of 2.82.

In other news, CFO Gil M. Labrucherie sold 25,000 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $33.71, for a total value of $842,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Howard W. Robin sold 100,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $33.00, for a total value of $3,300,000.00. Following the sale, the chief executive officer now directly owns 328,659 shares in the company, valued at $10,845,747. The disclosure for this sale can be found here. Insiders sold a total of 184,949 shares of company stock worth $6,075,350 in the last three months. Company insiders own 4.02% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of Nektar Therapeutics by 8.5% during the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock worth $853,355,000 after purchasing an additional 2,041,954 shares during the period. Vanguard Group Inc boosted its stake in shares of Nektar Therapeutics by 3.6% during the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after acquiring an additional 660,907 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Nektar Therapeutics by 11.6% during the 4th quarter. First Trust Advisors LP now owns 2,309,172 shares of the biopharmaceutical company’s stock worth $75,902,000 after acquiring an additional 240,272 shares in the last quarter. Norges Bank bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth about $63,723,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Nektar Therapeutics by 1.3% during the 4th quarter. Bank of New York Mellon Corp now owns 1,418,699 shares of the biopharmaceutical company’s stock worth $46,634,000 after acquiring an additional 17,670 shares in the last quarter. 92.23% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Further Reading: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.